Takeda UK Ltd.: NICE recommends Revestive ? (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)

Takeda UK Ltd. is pleased to announce that NICE has recommended the use of Revestive ? (teduglutide) once daily subcutaneous injection as an option for people living with Short Bowel Syndrome

Related Keywords

Japan ,United Kingdom ,London ,City Of ,Scotland ,Simon Gabe ,Susan Hill ,Carolyn Wheatley ,Mary Foss ,European Parliament ,European Commission ,Prnewswire Takeda United Kingdom Ltd ,Takeda Pharmaceutical Company ,National Health Service ,European Medicines Association ,National Institute For Health ,Takeda United Kingdom Ltd ,Scottish Medicines Consortium ,Takeda United Kingdom ,Short Bowel Syndrome ,National Institute ,Care Excellence ,Final Appraisal Document ,Short Bowel Survivor ,Consultants Dr Simon Gabe ,Lennard Jones Intestinal Rehabilitation Unit ,Paediatric Gastroenterologist ,Great Ormond Street Hospital ,Teduglutide Effectiveness ,Peter Wheatley Price ,Market Access Director ,United Kingdom Summary ,Product Characteristics ,Market Authorisation ,Pharmaceutical Company Limited ,Plasma Derived Therapies ,Accessed June ,Accessed May ,Pediatric Patients ,Intestinal Failure ,Liver Disease ,Contributing Factors ,Patients Receiving Home Parenteral Nutrition ,Permanent Intestinal Failure ,Shire Receives Extension ,Market Authorization ,Paediatric Patients ,Takeda ,Ice ,Ecommends ,Evestive ,Eduglutide ,Treatment ,Adults ,Children ,Diving ,Short ,Towel ,Yndrome ,